Full coverage· Health· Updated
US FDA Warns of Rare Vision Loss Risk with Popular Diabetes and Weight-Loss Drugs
The U.S. FDA is requiring new warnings on popular diabetes and weight-loss drugs like Ozempic and Wegovy due to a rare risk of vision loss. The condition, NAION, can cause sudden, irreversible damage.
2 newsrooms · 2 languages · since
Plus
What happened
- 01US FDA mandates new warnings for Ozempic, Wegovy, Mounjaro, and Zepbound over rare vision loss risk.
- 02The rare condition NAION can lead to sudden, potentially irreversible vision loss.
- 03Israeli diabetes nurses urge patients not to stop medication unsupervised due to greater immediate risks.
- 04The FDA's decision follows reviews of clinical trials and post-market adverse event reports.
- 05Patients experiencing sudden vision changes should seek immediate medical attention and consult doctors.
Israeli diabetes nurses advise patients against stopping medication without consulting doctors, citing greater immediate risks. The drugs' popularity is linked to a changing view of obesity as a complex medical condition.
The coverage
2 newsrooms on this story
Who covered it
- LeftNone
- Centre1
- Right1
- HarediNone
- ArabNone
How it broke
See which of the 2 newsrooms broke it, and who waited